[1]Bennett J, Kirby-Allen M, Ng V, Waye JS, Chung CT and Shaikh F. Hepatoblastoma in a Child With Early-onset Cirrhosis. J Pediatr Hematol Oncol 2019; 41: e30-e33.
[2]De Ioris M, Brugieres L, Zimmermann A, Keeling J, Brock P, Maibach R, Pritchard J, Shafford L, Zsiros J, Czaudzerna P and Perilongo G. Hepatoblastoma with a low serum alpha-fetoprotein level at diagnosis: the SIOPEL group experience. Eur J Cancer 2008; 44: 545–550.
[3]Ang JP, Heath JA, Donath S, Khurana S and Auldist A. Treatment outcomes for hepatoblastoma: an institution’s experience over two decades. Pediatr Surg Int 2007; 23: 103–109.
[4]Otte JB, Pritchard J, Aronson DC, Brown J, Czauderna P, Maibach R, Perilongo G, Shafford E, Plaschkes J and International Society of Pediatric O. Liver transplantation for hepatoblastoma: results from the International Society of Pediatric Oncology (SIOP) study SIOPEL–1 and review of the world experience. Pediatr Blood Cancer 2004; 42: 74–83.
[5]Otte JB, de Ville de Goyet J and Reding R. Liver transplantation for hepatoblastoma: indications and contraindications in the modern era. Pediatr Transplant 2005; 9: 557–565.
[6]Zhang B, He Q, Shi X, Wang X and Zhang X. Recurrent Scapular Metastasis From Hepatoblastoma Shown on FDG PET/CT and F-DOPA PET/CT. Clin Nucl Med 2017; 42: e449-e451.
[7]Liu B, Zhou L, Huang G, Zhong Z, Jiang C, Shan Q, Xu M, Kuang M and Xie X. Corrigendum: First Experience of Ultrasound-guided Percutaneous Ablation for Recurrent Hepatoblastoma after Liver Resection in Children. Sci Rep 2016; 6: 33424.
[8]Figarola MS, McQuiston SA, Wilson F and Powell R. Recurrent hepatoblastoma with localization by PET-CT. Pediatr Radiol 2005; 35: 1254–1258.
[9]Niwa A, Umeda K, Awaya T, Yui Y, Matsubara H, Hiramatsu H, Watanabe K, Adachi S, Itoh T, Uemoto S and Nakahata T. Successful autologous peripheral blood stem cell transplantation with a double-conditioning regimen for recurrent hepatoblastoma after liver transplantation. Pediatr Transplant 2009; 13: 259–262.
[10]Umeda K and Watanabe K. Autologous peripheral blood stem-cell transplantation with a double-conditioning regimen for recurrent hepatoblastoma after liver transplantation—a valid therapeutic option or just too much?—author reply. Pediatr Transplant 2009; 13: 794–795.
[11]Zsiros J, Brugieres L, Brock P, Roebuck D, Maibach R, Child M, Morland B, Casanova M, Pariente D, Paris C, de Camargo B, Ronghe M, Zimmermann A, Plaschkes J, Czauderna P and Perilongo G. Efficacy of irinotecan single drug treatment in children with refractory or recurrent hepatoblastoma—a phase II trial of the childhood liver tumour strategy group (SIOPEL). Eur J Cancer 2012; 48: 3456–3464.
[12]Matsunaga T, Sasaki F, Ohira M, Hashizume K, Hayashi A, Hayashi Y, Mugishima H, Ohnuma N and Japanese Study Group for Pediatric Liver T. Analysis of treatment outcome for children with recurrent or metastatic hepatoblastoma. Pediatr Surg Int 2003; 19: 142–146.
[13]Dunn CL, Lucas JT, Jr., Clark H and McLean TW. Successful Radiofrequency Ablation for Recurrent Pulmonary Hepatoblastoma. Pediatr Blood Cancer 2015; 62: 2242.
[14]Madabhavi I, Patel A, Choudhary M, Aagre S, Revannasiddaiah S, Modi G, Anand A, Panchal H, Parikh S and Raut S. Paraneoplastic recurrent hypoglycaemic seizures: an initial presentation of hepatoblastoma in an adolescent male-a rare entity. Case Rep Pediatr 2014; 2014: 104543.
[15]Czauderna P, Otte JB, Roebuck DJ, von Schweinitz D and Plaschkes J. Surgical treatment of hepatoblastoma in children. Pediatr Radiol 2006; 36: 187–191.
[16]Malogolowkin MH, Katzenstein HM, Meyers RL, Krailo MD, Rowland JM, Haas J and Finegold MJ. Complete surgical resection is curative for children with hepatoblastoma with pure fetal histology: a report from the Children’s Oncology Group. J Clin Oncol 2011; 29: 3301–3306.
[17]Schnater JM, Aronson DC, Plaschkes J, Perilongo G, Brown J, Otte JB, Brugieres L, Czauderna P, MacKinlay G and Vos A. Surgical view of the treatment of patients with hepatoblastoma: results from the first prospective trial of the International Society of Pediatric Oncology Liver Tumor Study Group. Cancer 2002; 94: 1111–1120.
[18]WHO,WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland, World Health Orgnaization,1979,205–216.
[19]Hirschman BA, Pollock BH and Tomlinson GE. The spectrum of APC mutations in children with hepatoblastoma from familial adenomatous polyposis kindreds. J Pediatr 2005; 147: 263–266.
[20]Anna CH, Sills RC, Foley JF, Stockton PS, Ton TV and Devereux TR. Beta-catenin mutations and protein accumulation in all hepatoblastomas examined from B6C3F1 mice treated with anthraquinone or oxazepam. Cancer Res 2000; 60: 2864–2868.
[21]Semeraro M, Branchereau S, Maibach R et al, Relapses in hepatoblastoma patients:clinical characteristics and outcome-experience of the International Childhood Liver Tumors Strategy Group (SIOPEL).[J]. Eur J Cancer, 2013,49(4):915–922.
[22] Hishiki T, Matsunaga T, Sasaki F, et al. Outcome of hepatoblastomas treated using the Japanese Study Group for Pediatric Tumor (JPLT) protocol 2: Report from the JPLT. Pediatr Surg Int 2011;27:1–8.
[23]Meyers RL, Rowland JR, Krailo M, Chen Z, Katzenstein HM and Malogolowkin MH. Predictive power of pretreatment prognostic factors in children with hepatoblastoma: a report from the Children’s Oncology Group. Pediatr Blood Cancer 2009; 53: 1016–1022.
[24]Semeraro M, Branchereau S, Maibach R, Zsiros J, Casanova M, Brock P, Domerg C, Aronson DC, Zimmermann A, Laithier V, Childs M, Roebuck D, Perilongo G, Czauderna P and Brugieres L. Relapses in hepatoblastoma patients: clinical characteristics and outcome—experience of the International Childhood Liver Tumour Strategy Group (SIOPEL). Eur J Cancer 2013; 49: 915–922.
[25]Walhof CM, Van Sonderen L, Voute PA and Delemarre JF. Half-life of alpha-fetoprotein in patients with a teratoma, endodermal sinus tumor, or hepatoblastoma. Pediatr Hematol Oncol 1988; 5: 217–227.
[26] Rudolf Maibach, Derek Roebuck b, Laurence Brugieres, et al. Prognostic stratification for children with hepatoblastoma:The SIOPEL experience. European Journal of Cancer, 2012,48: 1543– 1549.
[27]Ortiz D, Harden A, Corrales-Medina FF, Saigal G, Tekin A and Garcia J. Pediatric patient with end-stage kidney disease secondary to Eagle-Barrett syndrome and metastatic unresectable hepatoblastoma treated successfully with chemotherapy and liver-kidney transplant. Pediatr Transplant 2018; 22:
[28]Papry A, Kamal M and Khalid MS. Hepatoblastoma in a child with dextrocardia and possible histopathological alteration reminiscent of hepatocellular carcinoma after neoadjuvant chemotherapy. Clin Case Rep 2018; 6: 1070–1073.
[29]Boucher AA, Mizuno T, Vinks AA, Goldstein SL, Tiao GM and Geller JI. Dose modifications and pharmacokinetics of adjuvant cisplatin monotherapy while on hemodialysis for patients with hepatoblastoma. Pediatr Blood Cancer 2019; 66: e27425.
[30]Yu Y, Zhao X, Zhang Y, Kang Y, Wang J and Liu Y. Antitumor activity of YM155, a selective survivin suppressant, in combination with cisplatin in hepatoblastoma. Oncol Rep 2015; 34: 407–414.
[31]Hiyama E, Ueda Y, Onitake Y, Kurihara S, Watanabe K, Hishiki T, Tajiri T, Ida K, Yano M, Kondo S, Oue T and Japanese Study Group for Pediatric Liver T. A cisplatin plus pirarubicin-based JPLT2 chemotherapy for hepatoblastoma: experience and future of the Japanese Study Group for Pediatric Liver Tumor (JPLT). Pediatr Surg Int 2013; 29: 1071–1075.
[32]Zsiros J, Brugieres L, Brock P, Roebuck D, Maibach R, Zimmermann A, Childs M, Pariente D, Laithier V, Otte JB, Branchereau S, Aronson D, Rangaswami A, Ronghe M, Casanova M, Sullivan M, Morland B, Czauderna P, Perilongo G and International Childhood Liver Tumours Strategy G. Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL–4): a prospective, single-arm, feasibility study. Lancet Oncol 2013; 14: 834–842.
[33]Kobrinsky NL, Sjolander DE, Goldenberg JA and Ortmeier TC. Successful treatment of doxorubicin and cisplatin resistant hepatoblastoma in a child with Beckwith-Wiedemann syndrome with high dose acetaminophen and N-acetylcysteine rescue. Pediatr Blood Cancer 2005; 45: 222–225.
[34]Neuwelt AJ, Wu YJ, Knap N, Losin M, Neuwelt EA, Pagel MA, Warmann S, Fuchs J, Czauderna P and Wozniak M. Using acetaminophen’s toxicity mechanism to enhance cisplatin efficacy in hepatocarcinoma and hepatoblastoma cell lines. Neoplasia 2009; 11: 1003–1011.
[35]Giorgio Perilongo, Rudolf Maibach, Elisabeth Shafford, et al. Cisplatin versus Cisplatin plus Doxorubicin for Standard-Risk Hepatoblastoma. New Englsnd Journal of Medicine, 2009,361:1662–70.